GSK: ViiV Healthcare Announces CHMP Positive Opinion for Vocabria + Rekambys, the First and Only Complete Long-Acting HIV Treatment, for Adolescents in Europe
December 17, 2024
December 17, 2024
LONDON, England, Dec. 17 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2024:
* * *
- Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year
- At just 65% globally, treatment coverage for 10 - 19-year-olds living with HIV is lagging behind UNAIDS's target, demonstrating nee . . .
* * *
- Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting regimen for the treatment of HIV, reducing dosing days from 365 to 6 per year
- At just 65% globally, treatment coverage for 10 - 19-year-olds living with HIV is lagging behind UNAIDS's target, demonstrating nee . . .